Program Director

Stephen Harrison

Visiting Professor of Hepatology Radcliffe Department of Medicine, University of Oxford, UK
Medical Director, Pinnacle Clinical Research, Texas, USA
President, Summit Clinical Research, Texas, USA

Dr Harrison earned his medical degree from the University of Mississippi School of Medicine.  He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University.  He is board certified in both Internal Medicine and Gastroenterology.

Dr Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.  He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.


Grants – Akero, Axcella, Cirius, CiVi, Cymabay, Enyo, Galectin, Galmed Research & Dev., Genfit, Gilead Sciences, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM, Northsea, Novartis, Novo Nordisk, Poxel Sagimet, Viking

Consulting – AgomAB, Akero, Alentis, Alimentiv, Altimmune, Axcella, Boston Pharma, B Riley, BVF Partners, Canfite, CiVi, Corcept, Cymabay, Echosens, Enyo, Fibronostics, Foresite, Fortress, Galectin, Genfit, Gilead, GNS, Hepion, Hightide, HistoIndex, Inipharm, Intercept, Ionis, Kowa, Madrigal, Metacrine, Microba, NGM, NorthSea, Novartis, Novo Nordisk, Nutrasource, Piper Sandler, Poxel, Prometic Pharma, Ridgeline, Sagimet, Sonic Incytes, Terns, Vikings

Faculty Member

Vlad Ratziu

Sorbonne Université, Paris, France

Vlad Ratziu is a Professor of Hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a 2-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.

Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is a member of the organising committee of the NASH–TAG meetings. He is a Co-Editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 330 articles in top-tier specialty journals.


Consulting – Novo Nordisk

Faculty member

Quentin Anstee

Professor of Experimental Hepatology, Newcastle University, UK
Honorary Consultant Hepatologist in the Liver Unit, the Newcastle upon Tyne Hospitals NHS, Foundation Trust, UK

Professor Quentin M. Anstee is the Chair of Experimental Hepatology and the Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK. A practicing clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital, where he leads one of the largest Non-Alcoholic Fatty Liver Disease (NAFLD) clinical services in the UK. He trained in medicine at University College London where he was awarded a First Class Honours degree and won First Prize in Medicine in the final MB BS examination.

Prof Anstee’s translational research has made major contributions across the pathophysiology, natural history, diagnosis and treatment of NAFLD. His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. He coordinates two major international research consortia that are studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017-2022). He has established a pan-European NAFLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for NAFLD. He is an Associate Editor of the Journal of Hepatology.


Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multi-stakeholder consortium includes industry partners.

Grants – Allergan/Tobira, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd.

Consulting – 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics.

Speaker – Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape.

Royalties – Elsevier Ltd

Faculty Member

Manal Adbelmalek

Professor of Medicine, Mayo Clinic, USA

Manal F. Abdelmalek, MD, MPH, FAASLD is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University. Since first reporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogenic cirrhosis nearly 25 years ago, her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials, including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. She collaborates extensively to translate new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA, and biomarker development companies in the area of diagnostics and therapeutics for NASH. She is the lead Principal Investigator on several multicenter global studies, a member of the AASLD Global Outreach and Engagement Committee and past member of the AASLD Clinical Research Committee. As a teacher and educator, she has mentored clinical residents, fellows, faculty at rank of Assistant / Associate Professor from Duke University as well as other institutions in the study and research of liver disease. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN) for the past 15 years. Dr. Abdelmalek has published more than 200 manuscripts and currently serves on the Editorial Board of HEPATOLOGY, the official journal of the AASLD. 


Grants / Honoraria – Intercept, Madrigal, Hanmi, Viking, NovoNordisk, NGM Bio, Allergan, Galmed, Novartis, Durect, Poxel, Progenity, Target Pharma, Inventiva, Enanta, Enyo, Celgene, Genentech, Boehringer-Ingelheim

Sign up for new content alerts

This activity is supported by an educational grant from NOVO NORDISK A/S.